Stephan Wenninger
Munich, BY 80336, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 60 publications
Nociceptive pain in late-onset Pompe disease: prevalence, distribution, and clinical correlates.
Journal: Journal of neurology
Published: June 10, 2026
Respiratory insufficiency and sleep impairment in facioscapulohumeral muscular dystrophy.
Journal: Neuromuscular disorders : NMD
Published: February 09, 2026
First multicenter real-world analysis of switching to next-generation enzyme replacement therapies in late-onset Pompe disease.
Journal: Journal of neurology
Published: November 19, 2025
Clinically important improvements in 6-minute walk distance and forced vital capacity in adults with late-onset Pompe disease switching from alglucosidase alfa to cipaglucosidase alfa plus miglustat in the PROPEL study.
Journal: Neuromuscular disorders : NMD
Published: September 05, 2025
Management of hypersensitivity in a patient with late-onset Pompe disease experiencing recurrent infusion-related reactions.
Journal: Journal of neurology
Published: July 29, 2025
Miglustat: a first-in-class enzyme stabilizer for cipaglucosidase alfa for the treatment of late-onset Pompe disease.
Journal: Therapeutic advances in rare disease
Published: July 02, 2025
Efficacy and safety of respiratory strength and endurance training in patients with myotonic dystrophy type 1 (DM1): a randomized controlled trial.
Journal: Journal of neurology
Published: June 06, 2025
International collaboration to improve knowledge on myotonic dystrophy type 2.
Journal: Journal of neuromuscular diseases
Published: February 20, 2025
The assistive gait devices and their implementation in activities of daily living for patients with neuromuscular disease: A systematic review and meta-analysis.
Journal: Journal of neuromuscular diseases
Published: February 20, 2025
Efficacy of Switching Therapy From Alglucosidase Alfa to Avalglucosidase Alfa on Respiratory Function in Participants With Late-Onset Pompe Disease: A Post Hoc Analysis From the COMET Trial.
Journal: JIMD reports
Published: January 23, 2025
Updated Structure of CNBP Repeat Expansions in Patients With Myotonic Dystrophy Type 2 and Its Implication for Standard Diagnostics.
Journal: Neurology. Genetics
Published: September 26, 2024
Real-world evidence for Pompe disease remains fragmented. Comment on "A rare partnership: patient community and industry collaboration to shape the impact of real-world evidence on the rare disease ecosystem" by Klein et al.
Journal: Orphanet journal of rare diseases
Published: August 26, 2024
Last Updated: 09/26/2026